1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). - Riess, J.W.; Spicer, J.; Seiwert, T.; Villaflor, V.; Rubio Perez, J.; Shaw, P.H.; Soria Rivas, A.; Chaney, M.; Abildgaard, C.; Patel, P.; Iglesias, M.; Ahmad, Q.; et al. (Annals of Oncology, 2024)